BioInformant

Your Global Leader in Stem Cell Market Research

Irvine Scientific Introduces Chemically-Defined Natural Killer Cell Expansion Medium for Immunotherapy & Translational Research Applications

By Leave a Comment

The first chemically-defined, animal component-free cell culture medium for natural killer (NK) cells

Irvine Scientific

July 2018, Santa Ana, Calif. — Irvine Scientific, an industry leader in the development and manufacture of cell culture media, announced the introduction of PRIME-XV® NK Cell CDM— the first commercially available chemically-defined (CDM), animal component-free (ACF) medium for the ex vivo expansion of NK cells. The advanced medium delivers natural killer (NK) cell expansion while preserving NK cell potency and functionality. [Read more…]

Sangamo Therapeutics to Acquire Regulatory T Cell Leader TxCell for €72 Million

By Leave a Comment

TxCellSangamo Therapeutics (Nasdaq: SGMO) has announced it is acquiring TxCell S.A. (ENXTPA: TXCL) in a deal worth approximately €72 million. The deal is expected to be completed by the fourth quarter of 2018.

This acquisition will combine Sangamo’s unique ex vivo (outside the body) gene editing technology with TxCell’s CAR-Treg prowess, making Sangamo a new global leader in the Treg sector. [Read more…]

Exosomics Siena Launches Exosome-Based Liquid Biopsy Solutions for Selective Analysis of Tumor-Derived DNA and RNA

By Leave a Comment

  • Lonza Pharma & Biotech backs Exosomics Siena S.p.A. as they launch first products for next-generation research and diagnostic applications.

  • Exosomics Siena’s technology to bring new, highly selective solutions for cancer detection, characterization and monitoring.

Exosomics Siena tumor-derived exosomesSiena (IT) and Basel (CH), 13 July 2018 – Exosomics Siena S.p.A., a pioneer and world leader in exosome-based diagnostics, today announced the launch of its first proprietary liquid biopsy solutions, SeleCTEV™ DNA and SortEV™ RNA, for the selective isolation of tumor-derived nucleic acids from complex biofluids such as plasma or serum. [Read more…]

Live at The American Association of Stem cell Physicians (AAOSCP)

By Leave a Comment

AAOSCP 2018 SummitThe American Association of Stem Cell Physicians (AAOSCP) is an organization created to advance research and the development of therapeutics in regenerative medicine, including diagnosis, treatment, and prevention of disease related to or occurring within the human body. The AAOSCP aims to serve as an educational resource for physicians, scientists, and the public in diseases that can be caused by physiological dysfunction that are ameliorable to medical treatment.

The organization’s annual summit will be held this year at the Mandarin Oriental Miami, Florida, from Friday, August 10th to Sunday, August 12th, 2018.

One of the highlights of the summit will be a live webcast titled “Clinical Immortality 2029” that will feature world-class experts on stem cells, longevity, and clinical immortality. [Read more…]

Aegle Therapeutics Prepares Phase 1/2a Trial of BM-MSC Derived Extracellular Vesicles

By Leave a Comment

Aegle TherapeuticsAegle Therapeutics Corporation is the first extracellular vesicle (EV) company to be cleared by the FDA to enter clinical trials in humans. Headquartered in Miami, FL, the company is using allogeneic bone marrow mesenchymal stem cell (BM-MSC) derived extracellular vesicles to treat severe dermatological disorders, with a focus on burn treatments.

In May 2018, Aegle announced that the FDA cleared its first Investigational New Drug (IND) application to initiate a clinical trial in severe second degree burn patients. The company plans to launch a Phase 1/2a clinical trial of its lead product AGLE-102 in late 2018.

The open label dose escalation study will enroll patients at several sites in the U.S., evaluating the safety of extracellular vesicle therapy in burn patients. [Read more…]

Shopping cart0
There are no products in the cart!
Continue shopping
0